Business Acquisitions Hilger Crystals/ Dynasil Biomedical

9 Months Ended

Jun. 30, 2011

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

Note 10 – Business Acquisitions – Hilger Crystals/ Dynasil Biomedical

Hilger Crystals, Ltd.

On July 19, 2010, Dynasil completed the acquisition of 100% of the issued and outstanding common stock of Hilger Crystals Limited (“Hilger”) from Newport Corporation (“Newport”).  Hilger, located in Margate, Kent, England, is engaged in the manufacture of synthetic crystals, detectors and arrays for infrared spectroscopy and x-ray and gamma ray detection.

The following is the comparative financial information of the Company for the nine months ended June 30, 2011 and the proforma financial information for the nine months ended June 30, 2010, assuming the transaction had been consummated at the beginning of the year (i.e., October 1, 2009.)

	For the nine months ended June 30, 2011 (Unaudited)			For the nine months ended June 30, 2010 (Unaudited)
Statement of Operations:
Revenue	$	35,896,030		$	33,546,984
Cost of revenue		21,136,257			19,854,674
Gross profit		14,759,773			13,692,310
Operating Expense		12,978,126			10,271,760
Income from operations		1,781,647			3,420,550
Interest expense, net		461,916			455,133
Income before taxes		1,319,731			2,965,417
Income taxes		(478,342	)		1,139,367
Net Income	$	1,798,073		$	1,826,050
Earnings per share:
Basic	$	0.12		$	0.15
Diluted	$	0.12		$	0.12

Dynasil Biomedical

On April 14, 2011, Dynasil announced the incorporation of Dynasil Biomedical Corp. as a new business unit to pursue opportunities in the medical field.  Through a purchase of assets, Dynasil Biomedical completed the purchase of specific rights to six biomedical technologies invented or co-invented by Dr. Daniel Ericson.  Dr. Ericson has joined Dynasil Biomedical as Scientific Lead for research and development.  The asset purchase had no impact on the comparative financial information reported above.